Actinium Pharmaceuticals & United States — Food and Drug Administration
3 shared events · Importance 3 · Last updated Apr 24, 2025
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Business
Actinium Pharmaceuticals: Actinium Pharmaceuticals is the defendant in a class action lawsuit alleging misleading statements regarding its Iomab-B Biologics License Application and Sierra Trial data, which could lead to significant financial and reputational damage.
Mar 28, 2025 · 6 articles
Business
Actinium Pharmaceuticals: Actinium Pharmaceuticals is facing a class action lawsuit for allegedly issuing materially false and/or misleading statements regarding its Iomab-B BLA and the Phase 3 Sierra trial data, which could negatively impact its stock price and reputation.
Apr 09, 2025 · 6 articles
Business
Actinium Pharmaceuticals: Actinium Pharmaceuticals is the defendant in a class action securities lawsuit, facing allegations of making false and misleading statements regarding its Iomab-B BLA and the Sierra trial data, which could negatively impact its stock price and reputation.
Apr 04, 2025 · 6 articles
NEWSDESK
Explore this relationship live
Track how Actinium Pharmaceuticals and United States — Food and Drug Administration interact across events, view sentiment trends, and discover connected entities.
Open Dashboard